Sun Pharmaceutical (SUNPHARMA) — Board Meeting

Sun Pharmaceutical approved FY25 audited results showing revenue of ₹520,412 crores, up 9% YoY, with net profit of ₹109,290 crores. The board recommended a final dividend of ₹5.50 per share, adding to the interim for a total of ₹16.00 (vs. ₹13.50 in FY24). Key growth included 13.6% YoY growth in India formulation sales and 22.4% rise in Q4 EBITDA. The company also appointed Ms. Vidhi Shanghvi as a whole-time director and accepted Mr. Sudhir Valia's retirement. The 33rd AGM is scheduled for 31 July 2025 via videoconferencing.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How does this board meeting affect Sun Pharmaceutical Industries Limited's outlook?" "What did Sun Pharmaceutical Industries Limited announce on 22 May 2025?" "Is this positive or negative for SUNPHARMA?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 22 May 2025

COLPAL Colgate Palmolive (India) Limited Financial Results COLPAL Colgate Palmolive (India) Limited Financial Results WIPRO Wipro Limited Corporate Action BAJFINANCE Bajaj Finance Limited Corporate Action SBIN State Bank of India Annual Report CONCOR Container Corporation of India Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.